ASSESSMENT OF COMPARATIVE PATIENT SATISFACTION AND SIDE-EFFECTS ASSOCIATED WITH TAMSULOSIN VERSUS SILODOSIN THERAPY IN BENIGN PROSTATE HYPERPLASIA
Keywords:Benign prostate hyperplasia, International prostate symptom score, Patient perception of study medication, Silodosin, Tamsulosin
Objective: The aim of our study was to assess the comparative patient satisfaction and side-effects of the currently prescribed drugs – tamsulosin and silodosin for benign prostatic hyperplasia (BPH).
Methods: A prospective study was conducted in a total of 110 BPH patients from the Department of Urology for a period of 6 months. Fifty-five patients in each group received silodosin 8 mg or tamsulosin 0.4 mg once daily. Data were collected using a suitably designed pro forma and the patient satisfaction was assessed with patient’s perception of study medication (PPSM) scale. International prostate symptom score (IPSS) was used for assessing the severity of symptoms.
Results: The current study found that the treatment had a significant effect on improving scores of PPSM and IPSS at which all changes were significant at p<0.01 (paired t-test). An independent t-test showed that silodosin group had a greater improvement in PPSM scores – PPSM total by 40.4%, PPSM global by 43.7%, and PPSM pain by 0.39% which was supported by corresponding decline in IPSS scores. The side effects reported for tamsulosin were headache (5.5%), dizziness (5.5%), dry mouth (3.6%), and postural hypotension (14.4%) and those reported for silodosin were myalgia (5.5%), dizziness (7.3%), diarrhea (1.8%), and postural hypotension (10.9%).
Conclusion: Patient satisfaction was improved by both the alpha blockers but silodosin showed a significantly greater increase in patient satisfaction than tamsulosin. Thus, silodosin is the better drug of choice.
Dornbier R, Pahouja G, Branch J, McVary KT. The new American urological association benign prostatic hyperplasia clinical guidelines: 2019 update. Curr Urol Rep 2020;21:32.
De la Rosette JJ, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F, et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001;40:256-63.
Martinez M, Satheesh M. Prostate disease. In: Walker R, Whittlesea C, editors. Clinical Pharmacy and Therapeutics. 5th ed. London: Elsevier; 2012. p. 753-59.
Mary L, Roohollah S. Benign prostatic hyperplasia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiological Approach. 10th ed. New York: McGraw-Hill; 2017. p. 792-833.
Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, Retik A, Vaughan E, Wein A, editors. Campbell’s Urology. 8th ed. Philadelphia, PA: Saunders; 2002. p. 1297-336.
Griffiths K. Molecular control of prostate growth. In: Kirby R, McConnell J, Fitzpatrick JM, Roehrborn CG, Boyle P, editors. Textbook of Benign Prostatic Hyperplasia. 2nd ed. Oxford: Isis Medical Media; 1996. p. 23-56.
Kaplan SA. AUA guidelines and their impact on the management of BPH: An update. Rev Urol 2004;6:S46-52.
Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauchi A, Yamanishi T, et al. Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol 2011;18:741-56.
Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: Achievements and limitations. Rev Urol 2008;10:14-25.
Dunn CJ, Matheson A, Faulds DM. Tamsulosin: A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002;19:135-61.
Ramesh A. Patient counselling. In: Parthasarathi G, Karin NH, Milap CN, editors. A Textbook of Clinical Pharmacy Practice: Essential Concepts and Skills. 1st ed. Hyderabad: Orient Blackswan; 2004. p. 60-71.
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;59:342-52.
Prakash B. Patient satisfaction. J Cutan Aesthet Surg 2010;3:151-5.
Mahajan P. Tadalafil therapy in symptomatic improvement of LUTS due to BPH and associated erectile dysfunction. J Med Sci Clin Res 2017;5:24577-82.
Nageratnam M, Latheef A. Prevalence of lower urinary tract symptoms in patients of Benign prostatic hyperplasia attending tertiary care hospital in the state of Andhra Pradesh. J NTR Univ Health Sci 2017;6:154-7.
Rossi M, Roumeguère T. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther 2010;4:291-7.
Narayan P, Tunuguntla HS. Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Rev Urol 2005;7:S42-8.
Lowe FC. Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol 2005;7:S13-21.
Montorsi F, Gandaglia G, Chapple C, Cruz F, Desgrandchamps F, Llorente C. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). Int J Urol 2016;23:572-9.
Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M. Issues in the measurement of satisfaction with treatment. Am J Manag Care 1997;3:579-94.
Shikiar R, Rentz AM. Satisfaction with medication: An overview of conceptual, methodologic, and regulatory issues. Value Health 2004;7:204-15.
Barkin J, Roehrborn CG, Siami P, Haillot O, Morrill B, Black L, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009;103:919-26.
Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome in elderly men: Toward better understanding and treatment. Drugs Aging 2003;20:1111-25.
Collins MM, Stafford RS, O’Leary MP, Barry MJ. Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: Results of a national survey of physician visits. Urology 1999;53:921-5.
Litwin MS, McNaughton-Collins M, Fowler FJ Jr., Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure. Chronic prostatitis collaborative research network. J Urol 1999;162:369-75.
Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial. Indian J Pharmacol 2014;46:601-7.
Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 2017;11:CD012615.
Patil SB, Ranka K, Kundargi VS, Guru N. Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study. Cent Eur J Urol 2017;70:259-63.
Yokoyama T, Hara R, Fujii T, Jo Y, Miyaji Y, Nagai A. Comparison of two different α1-adrenoceptor antagonists, tamsulosin and silodosin, in the treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A prospective randomized crossover study. Low Urin Tract Symptoms 2012;4:14-8.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.